ADAP
Price
$0.25
Change
+$0.01 (+4.17%)
Updated
Jul 3 closing price
Capitalization
66.26M
32 days until earnings call
AGIO
Price
$36.07
Change
+$0.72 (+2.04%)
Updated
Jul 3 closing price
Capitalization
2.09B
26 days until earnings call
Interact to see
Advertisement

ADAP vs AGIO

Header iconADAP vs AGIO Comparison
Open Charts ADAP vs AGIOBanner chart's image
Adaptimmune Therapeutics
Price$0.25
Change+$0.01 (+4.17%)
Volume$459.96K
Capitalization66.26M
Agios Pharmaceuticals
Price$36.07
Change+$0.72 (+2.04%)
Volume$258.71K
Capitalization2.09B
ADAP vs AGIO Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. AGIO commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and AGIO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ADAP: $0.25 vs. AGIO: $36.07)
Brand notoriety: ADAP and AGIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 43% vs. AGIO: 46%
Market capitalization -- ADAP: $66.26M vs. AGIO: $2.09B
ADAP [@Biotechnology] is valued at $66.26M. AGIO’s [@Biotechnology] market capitalization is $2.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileAGIO’s FA Score has 1 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • AGIO’s FA Score: 1 green, 4 red.
According to our system of comparison, AGIO is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while AGIO’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 6 bearish.
  • AGIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both ADAP and AGIO are a bad buy in the short-term.

Price Growth

ADAP (@Biotechnology) experienced а +3.22% price change this week, while AGIO (@Biotechnology) price change was +7.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

AGIO is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($2.09B) has a higher market cap than ADAP($66.3M). AGIO YTD gains are higher at: 9.769 vs. ADAP (-53.592). ADAP has higher annual earnings (EBITDA): -50.18M vs. AGIO (-434.71M). AGIO has more cash in the bank: 893M vs. ADAP (59.6M). ADAP has less debt than AGIO: ADAP (48.7M) vs AGIO (52.9M). ADAP has higher revenues than AGIO: ADAP (180M) vs AGIO (37M).
ADAPAGIOADAP / AGIO
Capitalization66.3M2.09B3%
EBITDA-50.18M-434.71M12%
Gain YTD-53.5929.769-549%
P/E RatioN/A3.13-
Revenue180M37M486%
Total Cash59.6M893M7%
Total Debt48.7M52.9M92%
FUNDAMENTALS RATINGS
ADAP vs AGIO: Fundamental Ratings
ADAP
AGIO
OUTLOOK RATING
1..100
5370
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9717
PRICE GROWTH RATING
1..100
9146
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (42) in the Biotechnology industry is in the same range as ADAP (52). This means that AGIO’s stock grew similarly to ADAP’s over the last 12 months.

AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that AGIO’s stock grew similarly to ADAP’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for ADAP (97). This means that AGIO’s stock grew significantly faster than ADAP’s over the last 12 months.

AGIO's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for ADAP (91). This means that AGIO’s stock grew somewhat faster than ADAP’s over the last 12 months.

AGIO's P/E Growth Rating (79) in the Biotechnology industry is in the same range as ADAP (100). This means that AGIO’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPAGIO
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 6 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 5 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PINDX20.280.27
+1.35%
Victory Pioneer Disciplined Growth A
FLRYX43.110.43
+1.01%
Nuveen Large Cap Select I
WISGX21.460.20
+0.94%
Segall Bryant & Hamill Small Cap GrInstl
PNGYX16.180.01
+0.06%
Putnam International Value Y
BTMPX18.16-0.02
-0.11%
iShares MSCI EAFE Intl Idx Inv P

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+3.14%
AKBA - ADAP
41%
Loosely correlated
-0.28%
ORMP - ADAP
36%
Loosely correlated
+0.93%
CSLLY - ADAP
32%
Poorly correlated
+0.99%
AXON - ADAP
31%
Poorly correlated
+2.70%
NTLA - ADAP
30%
Poorly correlated
+0.09%
More

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with LGND. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then LGND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
+2.04%
LGND - AGIO
51%
Loosely correlated
+0.81%
ZYME - AGIO
49%
Loosely correlated
+1.16%
CRNX - AGIO
46%
Loosely correlated
+1.22%
VRDN - AGIO
46%
Loosely correlated
+2.89%
AXON - AGIO
45%
Loosely correlated
+2.70%
More